Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 Next >
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Jefferies Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports First Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in JMP Securities Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Launches New Scientific Website
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.